Jci_page_head_homepage_01 Jci_page_head_homepage_02
Niklas Finnberg, Andres J.P. Klein-Szanto, Wafik S. El-Deiry
Published in Volume 118, Issue 1
J Clin Invest. 2008; 118(1):111–123 doi:10.1172/JCI29900
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3
WT Eμ-myc lymphomas are resistant to TRAIL in vitro and express high levels of FLIPs.

(A) Challenging isolated WT Eμ-myc lymphoma cells in vitro with TRAIL resulted in lack of cell death (as determined by tryphan blue staining) in comparison with treatment with etoposide. (B) In vitro cell death assays. Propidium iodide uptake (red staining) and fluorescent-labeled inhibitor of caspase activity (FLICA or FITC-VAD-FMK; green staining) suggest that TRAIL (1 μg/ml) only weakly triggers caspase activity and cell death relative to control in comparison with treatment with etoposide (1 μM) in living Eμ-myc lymphoma cells. (C) Total RNA isolated from WT western blot of splenic and thymic lymphomas shows increased expression of c-FLIPS in WT relative to TRAIL-R+/– lymphomas. (D) Densitometric analysis using NIH ImageJ of western blots from lymphomas (splenic and thymic) from WT (n = 10) and TRAIL-R+/– (n = 10) mice. The ratios of the FLIPs band in relation to the actin band (loading control) is shown. The red horizontal band represents median, and the red cross represents the mean. WT lymphomas have a higher FLIPs/actin ratio (P < 0.05, Student’s t test), suggesting a relatively higher FLIPs expression compared with TRAIL-R+/– lymphomas.